Glad to see this collaborative effort with @datsunian @A_SteinMerlob and our wonderful coauthors online!
New online! Cardiotoxicity of T cell immunotherapies dlvr.it/TR74rrView quoted post on X
@MichaelR21
New online! Cardiotoxicity of T cell immunotherapies dlvr.it/TR74rrView quoted post on X
Exciting research news!View quoted post on X
DoM fellow, Dr. Michael Raddatz, and his team published groundbreaking research in @JClinicalInvest uncovering how CHIP mutations increase the risk of aortic valve disease. Their work could lead to new preventive treatments: uclahs.fyi/49JfFhi
#ClonalHematopoiesis of indeterminate potential (CHIP) is common in older individuals, but its connection with aortic valve stenosis was unclear.View quoted post on X
Here, @AlexBickMDPhD @StefanieDimmel1 @AndreasZeiher @cpi_exstra reveal an association between TET2 mutations and aortic valve stenosis (n=886,378), showing #CHIP activates procalcific pathways in macrophages and promotes aortic valve stenosis: jci.org/articles/view/…
The figure shows increased aortic valve calcification (OSM, green) and inflammation (S100A9, red) in a CHIP TET2-mutant mouse model; nuclei (DAPI, blue).
We still don't measure CHIP in the clinic (blood stem cell clones) which occur frequently with age and are a risk factor for cancer and heart disease. Here's how CHIP can lead to a calcified aortic valve. @jclinicalinvestView quoted post on X
jci.org/articles/view/…
Seeing this in real time at VUMC where 1 in 5 cath lab patients have CHIP. We're building care pathways but standardization across centers would help. Curious what others are doing for longitudinal follow-up. @MichaelR21 @pnatarajanmd @AlexBickMDPhDView quoted post on X